Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Purpose:

We evaluated the long-term outcomes of treatment of lower urinary tract symptoms due to benign prostatic hyperplasia to compare a 1-time water vapor thermal therapy procedure with daily medical therapy in cohorts from the MTOPS (Medical Therapy of Prostatic Symptoms) study.

Materials and Methods:

Results in the treatment arm of a randomized, controlled trial of thermal therapy using the Rezūm® System were compared to MTOPS subjects treated with doxazosin and/or finasteride. Evaluations were restricted to medical therapy subjects, representing 1,140 of the original 3,047 (37.4%), with a prostate volume of 30 to 80 cc and an International Prostate Symptom Score of 13 or greater to include men who met key criteria of the Rezūm and MTOPS trials. Outcomes were compared during 3 years for symptom changes and clinical progression rates.

Results:

Thermal therapy improved symptom scores by approximately 50% throughout 36 months (p <0.0001). Symptom improvement was greater than with either drug alone but similar to that of combination drugs (p ≤0.02 and 0.73, respectively). The peak flow rate improved 4 to 5 ml per second after thermal therapy and doxazosin while thermal therapy was superior to finasteride and combination drugs for 24 and 12 months (p <0.001 and <0.01, respectively). Observed rates of clinical progression during 3 years corroborate these outcomes with approximately 5 times greater progression for any medical therapy vs a single thermal therapy procedure.

Conclusions:

A single water vapor thermal therapy procedure provided effective and durable improvements in symptom scores with lower observed clinical progression rates compared to daily long-term use of pharmaceutical agents.

References

  • 1 : Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol2003; 44: 539. Google Scholar
  • 2 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med1996; 335: 533. Google Scholar
  • 3 : Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61: 119. Google Scholar
  • 4 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Google Scholar
  • 5 : The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol2010; 57: 123. Google Scholar
  • 6 : Comparison of alpha-blocker monotherapy and alpha-blocker plus 5alpha-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res2012; 40: 899. Google Scholar
  • 7 : National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology2012; 79: 1111. Google Scholar
  • 8 : Transurethral convection water vapor as a treatment for lower urinary tract symptomology due to benign prostatic hyperplasia using the Rezūm® system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol2015; 7: 13. Google Scholar
  • 9 : Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology2015; 86: 122. Google Scholar
  • 10 : Minimally invasive prostate convective water vapor energy (WAVE) ablation: a multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol2016; 195: 1529. LinkGoogle Scholar
  • 11 : Erectile and ejaculatory function preserved with convective water vapor energy treatment of LUTS secondary to BPH: randomized controlled study. J Sex Med2016; 13: 924. Google Scholar
  • 12 : Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol2017; 197: 1507. LinkGoogle Scholar
  • 13 : Procedural techniques and multicenter post-market experience using minimally invasive convective radiofrequency thermal therapy with Rezūm System for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol2017; 9: 159. Google Scholar
  • 14 : Three-year outcomes of the prospective, randomized controlled Rezūm System study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology2018; 111: 1. Google Scholar
  • 15 : Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials2003; 24: 224. Google Scholar
  • 16 : An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res2011; 46: 399. Google Scholar
  • 17 : Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol2015; 68: 418. Google Scholar
  • 18 : 5-Alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med2008; 5: 2917. Google Scholar
  • 19 : Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol2009; 181: 2214. LinkGoogle Scholar
  • 20 : Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Clin Pract2014; 68: 197. Google Scholar
  • 21 : Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido inpatients with LUTS/BPH: a systematic review with meta-analysis. Aging Male2016; 19: 175. Google Scholar
  • 22 : A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int2018; 121: 647. Google Scholar
  • 23 : Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract2006; 60: 1157. Google Scholar
  • 24 : Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract2008; 62: 18. Google Scholar
  • 25 : Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res2018; 10: 29. Google Scholar
  • 26 : Perspective on the Rezūm System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Dev (Auckl)2017; 10: 71. Google Scholar
  • 27 : Can long-term LUTS/BPH pharmacological treatment alter the outcomes of surgical intervention?. Curr Urol Rep2017; 18: 72. Google Scholar
  • 28 : A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med1995; 332: 75. Crossref, MedlineGoogle Scholar
Advertisement